Dr. Scherber on the Treatment of Myelofibrosis

Video

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment of patients with myelofibrosis.

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment of patients with myelofibrosis.

Scherber says that the treatment approach to myelofibrosis is 2-fold. First, risk must be assessed. Risk scoring methods such as the Dynamic International Prognostic Scoring System are often used, and if the patient is early on in their course of disease, Scherber says she uses the International Prognostic Score. Once risk is determined, the treatment paradigm becomes clearer.

The other thing that is considered when choosing treatment for a patient with myelofibrosis is symptom burden. MPN10 is a 10-item assessment of symptoms with a 0 to 100 scoring system. If the collective total of the symptoms is greater than 20 out of 100, or any individual symptom is scored greater than 5, those patients may benefit from symptom-based therapy, explains Scherber.

Related Videos
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh